HLA-DRA is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLA-DRA status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

HLA-DRA is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain HLA-DRA status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open) [4].

HLA-DRA is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains HLA-DRA status and melanoma as inclusion criteria, 1 is phase 2 (0 open) [4].